Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A

Inclusion criteria

• Participants and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately.
• Male or female participants aged ≥ 2 to ≤11 years at the time of signing the informed consent form.
• Participants with a diagnosis of influenza virus infection confirmed by all of the following:

• Positive rapid antigen test (RAT) for influenza with nasal or throat swabs;
• The time interval between the onset of symptoms and enrollment is 48 hours or less;
• Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present

Exclusion criteria

• Participants with severe influenza virus infection；
• Participants with any medical history in gastrointestinal that interferes with the absorption of drugs；
• Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment；
• Have received any other investigational products within 3 months prior to dosing；
• Positive urine pregnancy test；
• Participants with concurrent infections requiring antimicrobial therapy；
• Participants who are considered inappropriate for the study by the investigator.